Latest Rufinamide Stories
WOODCLIFF LAKE, N.J., April 30, 2015 /PRNewswire/ -- Eisai Inc. and Eisai Co., Ltd.
WOODCLIFF LAKE, N.J., Feb.
-- Results of Investigational Studies of Perampanel and Rufinamide Accepted as Late-Breaking Posters -- WOODCLIFF LAKE, N.J., Dec. 5, 2014 /PRNewswire/ -- Eisai Inc.
Transparency Market Research added a new report "Global Epilepsy Therapeutics Market: Industry Analysis, Size, Share, Growth and Forecast 2019" to its report store.
LONDON, June 30, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
Tokyo, Dec 15, 2011 - (JCN Newswire) - Eisai Co.
HATFIELD, England, Jan. 25, 2011 /PRNewswire/ -- Eisai announced today that it will submit Marketing Authorization Applications in the United States and the European Union for the investigational compound perampanel (E2007) based on the results of three Phase III pivotal studies.
HATFIELD, England, January 13, 2011 /PRNewswire-FirstCall/ -- - Epilepsy Treatment Zonegran(R) First Commercially Available Product Eisai Europe Limited, a subsidiary of Eisai Co., Ltd (Headquarters: Tokyo; President and CEO: Haruo Naito) announces the establishment of its sales and marketing operation in its wholly owned subsidiary in the Netherlands based in Amsterdam.
Researchers from the Arkansas Epilepsy Program found treatment with rufinamide results in a significant reduction in seizure frequency compared with placebo, for patients with uncontrolled partial-onset seizures (POS).
- A hairdresser.